No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 89,234 | 74,979 | 76,034 | 72,984 | 72,044 | 94,035 | 76,871 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 19,370 | 13,405 | 9,549 | 5,440 | 8,025 | 13,945 | 2,144 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kaken Pharmaceutical Co., Ltd. (4521.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.
